Ever Supreme Bio Technology Co., Ltd. (6712.TWO)

Ever Supreme Bio Technology is a clinical-stage biotech company focused on developing next-generation allogeneic cell therapies for solid tumors. Its lead candidate, CAR001, combines gamma delta T cells targeting HLA-G with BiTE-mediated PD-L1 engagement to overcome two major barriers in current solid tumor treatment: tumor heterogeneity and immune evasion. With operations in Taiwan and early clinical trials underway, Ever Supreme also runs a revenue-generating CDMO platform and is expanding its pipeline to include stem cell and exosome-based therapies. Backed by a strong IP portfolio across seven countries and deep clinical expertise, the company is strategically positioned to deliver scalable, off-the-shelf immunotherapies that are safe, effective, and globally accessible.